Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to DevelopingCountries

By Pharmaceutical Processing | February 23, 2009

Schering-Plough Corporation has announced a license agreementbetween Nobilon, Schering-Plough’s human vaccine business unit, and the WorldHealth Organization (WHO) to provide access to pandemic influenza vaccinemanufacturing technology to developing countries. Fred Hassan, chairman and CEO, said, “This project demonstratesSchering-Plough’s strong commitment to innovation and to providing access tomedicines. The avian influenza virus is already affecting several developingcountries, making pandemic influenza vaccine preparedness a global healthpriority. Our collaboration with the WHO is most important because it is aimedat allowing many developing countries to gain access to proven influenzavaccine manufacturing platforms.” Under the agreement, which was signed recently at WHO headquarters inGeneva, Nobilon has granted WHO a non-exclusive license to develop, register,manufacture, use and sell seasonal and pandemic live, attenuated, influenzavaccines (LAIV), produced on embryonated chicken eggs. WHO will be permittedto grant a sub-license to vaccine manufacturers in developing countries working within the framework of the WHO Global Vaccine Action Plan…. Vaccinemanufacturers to whom a sub-license will be granted will be able to providevaccines to the public sector of developing countries royalty-free.Egg-based LAIV technology is specifically considered attractive for thispurpose because the manufacturing technology process is easier to transfer,capital investment is lower and yields are higher, as compared to inactivatedinfluenza vaccines. The WHO Global Vaccine Action Plan seeks to expand influenza vaccinemanufacturing capacity in developing countries and enhance the global supplyfor pandemic vaccines.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE